UPDATE: Burril Initiates Sarepta Therapeutics at Market Outperform on Eteplirsen Potential
Burril initiated coverage on Sarepta Therapeutics (NASDAQ: SRPT) with a Market Outperform rating and a $54 price target.
Burril commented, "Sarepta is currently in clinical trials evaluating Eteplirsen, a novel RNA splicing modulator poised to correct genetic mutations which result in a dysfunctional protein and cause diseases of large unmet need. To date, the company has demonstrated both safety and preliminary efficacy in Phase 1 and Phase 2 trials with patients amenable to Exon 51 therapy in Duchenne's Muscular Dystrophy (DMD). Given the final encouraging results from the 201/202 Phase 2 study, we believe shares are poised to move higher. If successful, we believe Sarepta's directed alternative splicing technology has the potential to revitalize the RNA therapeutics space and address multiple multi-billion dollar orphan disease markets."
Sarepta Therapeutics closed at $29.35 on Friday.
Latest Ratings for SRPT
|Jan 2016||RBC Capital||Downgrades||Outperform||Sector Perform|
|Jan 2016||Piper Jaffray||Downgrades||Overweight||Neutral|
|Nov 2015||Leerink Swann||Maintains||Market Perform|
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.